Assessment of Minimum Inhibitory Concentrations of Telavancin by Revised Broth Microdilution Method in Phase 3 Hospital-Acquired Pneumonia/Ventilator-Associated Pneumonia Clinical Isolates.

Smart, Jennifer I; Corey, Gordon Ralph; Stryjewski, Martin E; Wang, Whedy; Barriere, Steven L

Smart, Jennifer I; Corey, Gordon Ralph; Stryjewski, Martin E; Wang, Whedy; Barriere, Steven L.

Afiliación

Smart JI; Theravance Biopharma US, Inc., South San Francisco, CA, USA. jsmart@smartmicrobiology.com.
Corey GR; Duke University, Durham, NC, USA.
Stryjewski ME; Department of Internal Medicine and Division of Infectious Diseases, CEMIC, Buenos Aires, Argentina.
Wang W; Theravance Biopharma US, Inc., South San Francisco, CA, USA.
Barriere SL; Theravance Biopharma US, Inc., South San Francisco, CA, USA.

Infect Dis Ther ; 5(4): 535-544, 2016 Dec.

Article en En | MEDLINE | ID: mdl-27718118

Palabras clave

Hospital-acquired pneumonia; Lipoglycopeptide; Staphylococcus aureus; Telavancin; Ventilator-associated pneumonia

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Risk_factors_studies Idioma: En Revista: Infect Dis Ther Año: 2016 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google